Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High-risk pediatric ALL chemotherapy regimen
- Development stage
- Unknown
- Lead developer
- Jae Wook Lee
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intrathecal, Oral
01
Overview
The High-risk pediatric ALL chemotherapy regimen is a risk-stratified treatment protocol designed for newly diagnosed high-risk pediatric acute lymphoblastic leukemia (ALL). Developed under the leadership of Jae Wook Lee, this multi-center, nationwide study in South Korea evaluates a regimen where treatment intensity is adjusted based on minimal residual disease (MRD) levels. The protocol typically includes induction, consolidation, interim maintenance, and delayed intensification phases. A central component of the study is the MRD-guided use of doxorubicin during delayed intensification to optimize therapeutic efficacy while managing toxicity. The regimen combines several cytotoxic agents, including vincristine, prednisolone, L-asparaginase, daunorubicin, cyclophosphamide, cytarabine, mercaptopurine, and methotrexate, to target leukemic cells through multiple pathways such as DNA damage, metabolic inhibition, and mitotic disruption.
- Other names
- ALL, High riskMRD-guided delayed intensification with doxorubicin
02
Targets
DNATOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))DNA polymerase family
Beyond the preview
Go deeper on High-risk pediatric ALL chemotherapy regimen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on High-risk pediatric ALL chemotherapy regimen.